X @None

Moderna Shares Surge Pre-Market On Landmark Phase 3 Cancer Therapy Results$MRNA stock is set to almost double pre-market after news broke that the company's personalized mRNA cancer vaccine, developed with Merck, met all its objectives in a landmark Phase 3 clinical trial.This is a major milestone for oncology and could trigger a significant liquidity rush, as the equity market prices in the commercialization of personalized genomic medicine.The stock is now available for on-chain investors through @OndoFin ...